Sky-High Cost of College Explained

Sky-High Cost of College Explained

Top of Mind with Julie Rose - Radio Archive, Episode 902 , Segment 4

Episode: Drug Companies and Opioid Crisis, Online Public School, Investigative Journalism

  • Sep 18, 2018 9:00 pm
  • 23:25 mins

Guest: David Feldman, PhD, Professor of Economics, College of William and Mary It’s homecoming season on college campuses. Alumni are back to visit their old haunts and marvel at the new buildings and amenities added to the school since they graduated. Those fancy sports arenas, workout facilities and dining halls must be a main reason tuition is so much higher today, right? Well, actually, that’s a common misconception, according to economist David Feldman.

Other Segments

How Drug Companies Continue to Make the Opioid Crisis Worse

18 MINS

Guest: Robin Feldman, JD, Professor of Law, Director of the Institute for Innovation Law, University of California A prominent player in America’s opioid abuse problem, Purdue Pharma, is facing more than a thousand lawsuits from states and cities over its alleged role in fueling the opioid crisis with its prescription painkiller OxyContin. Now, Purdue notes that OxyContin accounts for less than two percent of opioid in the US. But it used to be much higher. And investigative reporting in a range of publications has shown how aggressively Purdue worked to expand opioid use in the US, even as the overdose crisis escalated. The Financial Times recently reported that a company affiliated with Purdue Pharma patented a new drug earlier this year to treat opioid addiction, meaning it could potentially profit off both sides of the opioid epidemic.

Guest: Robin Feldman, JD, Professor of Law, Director of the Institute for Innovation Law, University of California A prominent player in America’s opioid abuse problem, Purdue Pharma, is facing more than a thousand lawsuits from states and cities over its alleged role in fueling the opioid crisis with its prescription painkiller OxyContin. Now, Purdue notes that OxyContin accounts for less than two percent of opioid in the US. But it used to be much higher. And investigative reporting in a range of publications has shown how aggressively Purdue worked to expand opioid use in the US, even as the overdose crisis escalated. The Financial Times recently reported that a company affiliated with Purdue Pharma patented a new drug earlier this year to treat opioid addiction, meaning it could potentially profit off both sides of the opioid epidemic.